Funds
Active funds
Thuja Capital manages two early stage life sciences funds:
- Thuja Capital Healthcare Fund I (TCHF)
- Thuja Capital Healthcare Seed Fund I (TCHSF)
We are currently actively investing out of TCHF and TCHSF. TCHSF is backed by the Dutch government (TechnoPartner Seed facility, see http://www.technopartner.nl/). Its investments are restricted to companies that are based in The Netherlands. The TCHF operates as a “mother fund” and has the Benelux as a geographical target region for investment.
With TCHF and TCHSF we invest in early-stage medical life sciences companies active in the following fields:
- Therapeutics (chemical or biotechnological origin), novel applications thereof, novel formulations and formulation technologies
- Medical devices, medtech products
- Diagnostics, biomarkers
- Platform technologies in support of the above
We look for propositions which still require (clinical) development. Pure growth capital is not our focus.
AlpInvest Partners’ portfolio of early stage life sciences companies
AlpInvest Partners invested successfully in over 30 life sciences companies. This has been a highly successful portfolio: almost all companies were exited through public listing or merger & acquisition.Today only two companies remain in the portfolio. Thuja Capital operates as the exclusive manager of the AlpInvest Partners’ life sciences company portfolio. The fund is closed for new investments.